Table 2.
Baseline patient and fresh cycle characteristics according to late-proliferative phase serum estradiol level percentiles of the FET cycle.
| p ≤ 10 | p11–90 | p > 90 | p-value | |
|---|---|---|---|---|
| n = 98 | n = 673 | n = 83 | ||
| Maternal age (years, mean ± SD) |
31.0 ± 5.3 | 32.3 ± 4.6 | 34.0 ± 5.1 | 0.332 |
| BMI (mean ± SD) |
25.9 ± 5.0 | 25.1 ± 5.1 | 24.6 ± 5.0 | 0.473 |
| Parity (mean ± SD) |
0.4 ± 0.6 | 0.4 ± 0.6 | 0.3 ± 0.5 | 0.473 |
| Presence of irregular cycles | 43 (43.9%) | 277 (41.3%) | 35 (42.7%) | 0.964 |
| Indication for IVF/ICSI | ||||
| Male | 21 (21.4%) | 216 (32.1%) | 24 (28.9%) | 0.109 |
| PCOS | 12 (12.2%) | 156 (23.2%) | 18 (21.7%) | 0.060 |
| Endometriosis | 5 (5.1%) | 18 (2.7%) | 2 (2.4%) | 0.535 |
| Tubal | 8 (8.2%) | 45 (6.7%) | 6 (7.2%) | 0.859 |
| Ovulatory disorder | 11 (11.2%) | 49 (7.3%) | 9 (10.8%) | 0.260 |
| PGT | 27 (27.6%) | 175 (26.0%) | 29 (34.9%) | 0.213 |
| Unexplained | 21 (21.4%) | 86 (12.8%) | 6 (7.2%) | 0.017*† |
| Rank (mean ± SD) |
1.8 ± 1.0 | 1.9 ± 1.4 | 2.3 ± 1.6 | 0.032†‡ |
| Number of usable embryos (mean ± SD) |
4.7 ± 2.9 | 4.9 ± 3.0 | 5.1 ± 2.4 | 0.681 |
| Biochemical pregnancy rate (hCG positivity in case of immediate fresh transfer) |
22 (33.3%) | 165 (33.8%) | 22 (31.4%) | 0.925 |
Analysis performed: mixed-effects modeling to account for clustering of patients who performed more than one cycle.
SD, standard deviation; BMI, body mass index; PCOS, polycystic ovary syndrome; PGT, preimplantation genetic testing: hCG, human chorionic gonadotrophin.
Freeze-all cycles excluded for the biochemical pregnancy rate calculation.
p < 0.05 for the following pairwise comparisons.
*
≤ p10 vs. p11–p90;
†
≤ p10 vs. >p90; p11–p90 vs. >p90.